BB Biotech’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

BB Biotech’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$78M	Buy	696,976 +121,257	+21%	+$13.2M	1.96%	16
2018 Q4	$58M	Buy	575,719 +30,000	+5%	+$3.11M	1.86%	19
2018 Q3	$69M	Hold	545,719	–	–	1.82%	19
2018 Q2	$45.8M	Hold	545,719	–	–	1.32%	20
2018 Q1	$33.6M	Buy	545,719 +60,000	+12%	+$3.62M	0.93%	23
2017 Q4	$28.4M	Hold	485,719	–	–	0.8%	22
2017 Q3	$28.2M	Buy	485,719 +230,000	+90%	+$24.8M	0.78%	22
2017 Q2	$31M	Hold	255,719	–	–	0.95%	21
2017 Q1	$28.9M	Hold	255,719	–	–	0.95%	22
2016 Q4	$27.8M	Hold	255,719	–	–	1.03%	20
2016 Q3	$42.1M	Hold	255,719	–	–	1.48%	20
2016 Q2	$36.5M	Hold	255,719	–	–	1.44%	19
2016 Q1	$32.9M	Hold	255,719	–	–	1.31%	20
2015 Q4	$38.2M	Buy	255,719 +45,000	+21%	+$7.62M	1.08%	22
2015 Q3	$35M	Buy	210,719 +30,000	+17%	+$6.6M	1.11%	22
2015 Q2	$43.6M	Buy	180,719 +25,719	+17%	+$6.85M	1.18%	23
2015 Q1	$43.7M	Buy	+155,000	New	+$33.6M	1.3%	22

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BB Biotech's ICPT Position: Q1 2019 in Review

BB Biotech increased its Intercept Pharmaceuticals, Inc. (ICPT) stake by 21% in Q1 2019, buying an estimated $13.2M and bringing the position to 696,976 shares worth $78M. The position accounts for 1.96% of the portfolio, ranked #16.

BB Biotech first reported a position in ICPT in Q1 2015 and has held it in 17 quarters since. 202 funds tracked by Wall St. Rank hold ICPT as of Q1 2019.

BB Biotech held 696,976 shares of Intercept Pharmaceuticals, Inc. worth $78M as of Q1 2019.
BB Biotech bought 121,257 Intercept Pharmaceuticals, Inc. shares in Q1 2019, an estimated $13.2M.
Intercept Pharmaceuticals, Inc. made up 1.96% of BB Biotech's portfolio in Q1 2019, its #16 holding.
BB Biotech first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2015 and has held it in 17 quarters since.
202 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.